The individual and societal impact of cancer remains a problem of Herculean proportions and one that is expected to outpace cardiovascular disease as the primary killer of humans in developed nations. With such a rise in incidence comes the need for the rapid development of novel therapies. The advent of next-generation sequencing technologies has led to a rapid expansion of the molecular profiling of patients with cancer. Such modalities are not only available at most large institutions and comprehensive cancer centers; they are also freely accessible commercially through various companies to the practicing oncologist in the community. This newfound knowledge of somatic mutations within a patient’s molecular profile, as well as a rise in the fundamental understanding of the cellular processes behind cancer cell deregulation, have spurred the rapid growth of the development of novel targeted therapies.
Click here to view the full article